Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

BackgroundPreclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with immunotherapy.MethodsThis investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with untr...

Full description

Bibliographic Details
Main Authors: Saba S. Shaikh, Yan Zang, Janel Hanmer, Hong Wang, Yan Lin, Diwakar Davar, Hassane M. Zarour, John M. Kirkwood, Yana G. Najjar
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
targeted therapy
BRAF
melanoma
metastatic
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1022496/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1022496/full

Similar Items